A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the comparative efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine versus Praziquantel in the treatment of school children infected with S.mansoni in western Kenya.
| Condition | Intervention | Phase |
|---|---|---|
|
Schistosoma Mansoni |
Drug: Artesunate+Sulfamethoxypyrazine/pyrimethamine Drug: Praziquantel |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children |
- Compare the cure rate between the two treatment arms [ Time Frame: after 28 days ] [ Designated as safety issue: No ]
- Compare the proportion of children excreting schistosoma eggs between the two treatment arms [ Time Frame: after 28 days ] [ Designated as safety issue: No ]
- Compare the amount of eggs produced between the two arms [ Time Frame: after 28 days ] [ Designated as safety issue: No ]
- Compare the incidence of clinical and biological adverse events [ Time Frame: after 28 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 212 |
| Study Start Date: | October 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Artesunate+Sulfamethoxypyrazine/pyrimethamine |
Drug: Artesunate+Sulfamethoxypyrazine/pyrimethamine
Other Name: Co-arinate FDC
|
| Active Comparator: Praziquantel |
Drug: Praziquantel
Other Name: Biltricide
|
Detailed Description:
Schistosomiasis remains an important parasitic disease in the tropics, including Kenya. In the absence of a vaccine, the major control strategy is the reduction of morbidity by chemotherapy using Praziquantel. Evidence from laboratory studies and field trials continue to show that schistosome worms have developed reduced susceptibility to Praziquantel. These observations indicate the need for research to monitor the trends in efficacy of praziquantel and the need for research to develop novel antischistosomal drugs. Randomized controlled trials have also shown that Artemisinin derivatives (artesunate, artemether) have antischistosomal activity against S. mansoni, S. haematobium and S. japonicum. We propose to conduct an open-label, randomized trial to evaluate the comparative efficacy of artesunate plus sulfamethoxypyrazine-pyrimethamine versus Praziquantel in the treatment of 212 school children infected with S.mansoni in Rarieda district in western Kenya. To do this we will screen about 1000 school children by examination of stool for schistosome eggs. Eligible children will be randomized to receive either artesunate plus sulfamethoxypyrazine-pyrimethamine over 3 days or a single dose of Praziquantel. Four weeks after treatment, the participants will be assessed for cure and egg reduction.Our study may provide vital information regarding an alternative treatment for S. mansoni infection in children.
Eligibility| Ages Eligible for Study: | 6 Years to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged between 6 and 15 years old
- Study participants appear healthy at enrollment, as assessed by the study clinician
- Suffering from S. mansoni infection, excreting eggs in stool
- Residing in Uyoma area, near Lake Victoria
- Able to receive oral treatment
- Parent/legal guardian gives informed written consent for the child to participate in the study
- Child assent to participate in study
Exclusion Criteria:
- Weighing more than 50 kg
- Pregnant or lactating at the time of the study
- Presence of infection with Plasmodium falciparum or other Plasmodium spp.
- Presence of severe illness, such as cerebral cysticercosis
- Signs of severe malnutrition (defined as children with weight/height ratio below 3 standard deviations or below 70% of the median of the WHO standardized reference values, or still with symmetrical oedema affecting both feet)
- Hypersensitivity to As, sulfonamides or PZQ.
- Use of another anti-malaria or anti-schistosomal drug during the study, or within 28 days before the administration of treatment.
- Previous participation in this study.
Contacts and Locations| Kenya | |
| KEMRI Centre for Global Health Research | |
| Kisumu, Kenya | |
| Study Director: | Pauline N Mwinzi, PhD | Kenya Medical Research Institute |
More Information
No publications provided by Kenya Medical Research Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr Charles O. Obonyo, Kenya Medical Research Institute |
| ClinicalTrials.gov Identifier: | NCT01054651 History of Changes |
| Other Study ID Numbers: | KEMRI SSC 1582, DRD140 - S6.2008 |
| Study First Received: | January 21, 2010 |
| Last Updated: | January 21, 2010 |
| Health Authority: | Kenya: Ethical Review Committee |
Keywords provided by Kenya Medical Research Institute:
|
Schistosoma mansoni Praziquantel Artesunate + Sulfamethoxypyrazine/pyrimethamine Randomized open-label controlled clinical trial |
Additional relevant MeSH terms:
|
Schistosomiasis mansoni Schistosomiasis Trematode Infections Helminthiasis Parasitic Diseases Praziquantel Artesunate Pyrimethamine Sulfalene Anthelmintics Antiparasitic Agents |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antimalarials Antiprotozoal Agents Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents Amebicides |
ClinicalTrials.gov processed this record on May 16, 2013